| Filed On | Filing |
|---|---|
| 01 Jul 2024 |
8-K/A: Costs Associated with Exit or Disposal Activities
On June 25, 2024, Aerovate Therapeutics, Inc. (the “Company”) determined to implement a reduction of the Company’s workforce (the “Workforce Reduction Plan”) following the Company’s previously announced decision to shut down its Phase 2b... |
Loading...
